Connect with us

Diagnosis

Uterine cancer cases to surge 53 per cent

Published

on

Uterine cancer cases could rise by as much as 53 per cent by 2050, with diets high in junk food and obesity rates believed to be driving the increase.

Deaths from the disease are forecast to rise by between 83 and 98 per cent over the next 25 years among women aged 18 to 84.

The rate of increase is expected to outpace that of bowel cancer, which is growing by 2.4 per cent each year in under-50s but declining overall by about one per cent annually.

Meanwhile, average deaths from bowel cancer are seeing an annual decline of roughly 1 per cent – despite the rising toll of younger victims.

Dr Chris van Tulleken, expert in infectious disease and global health at University College London, said: “We have more than a dozen good quality studies indicating a link between cancer and ultra-processed foods.”

Black women are predicted to be disproportionately affected, with case numbers expected to climb by 53 per cent compared to 28.6 per cent in white women.

Deaths among black women could rise by 97.9 per cent, compared to 83.6 per cent in white women.

Researchers from Columbia University in the US built a model to help predict future rates of uterine cancer across the US.

The model was based on a population sample of women aged 18 to 84, who were born over the last 100 years.

They tracked disease incidence over the women’s lifetimes, including uterine cancer, and used annual increases in disease to project future diagnoses.

Lead author Dr Jason D Wright said the projections do not account for future advances in prevention or treatment that could reduce mortality.

The higher rates seen in black women may be linked to more aggressive forms of the disease and delays in diagnosis and treatment, according to scientists.

The overall increase is thought to be driven by obesity.

Cancer Research UK estimates that a third of womb cancer cases in the UK are linked to being overweight or obese.

Excess weight raises levels of hormones like fasting insulin and testosterone, which are known to encourage tumour growth in the uterus.

Obesity levels have doubled globally in both adults and children since 1990, with the rise in ultra-processed food consumption widely blamed.

These foods – such as cakes, crisps and ready meals – are typically high in calories, sugar, salt and fat, and usually include at least one ingredient not found in a standard kitchen.

Uterine cancer is the most common gynaecological cancer in high-income countries and the fourth most common among women in the UK. C

ancer Research UK estimates that 34 per cent of UK uterine cancer cases are preventable.

The researchers tested a screening scenario in which women were invited for checks to detect early signs of disease.

The approach was most effective when screening began at age 55, with rates of cancer falling for up to 15 years in white women and 16 years in black women.

Lead author of the study Dr Jason D Wright said: “The testing suggests that if there was an effective screening test, we may be able to substantially reduce the burden of disease.”

The findings come amid broader concerns about rising cancer rates in younger people.

Bowel cancer is increasing in under-50s in 27 of 50 countries studied, with England recording an average 3.6 per cent annual rise in younger adults.

Roughly 2 per cent yearly increases have also been reported in the US. Cancer Research UK figures show that diagnoses have risen by up to 23 per cent among people aged 20 to 49.

While the disease is known to be linked to obesity, experts note it also appears in fit and healthy patients.

Diagnosis

Gender gap in treatment persists even when men and women have same condition

Published

on

Women with the same medical conditions as men were less likely to receive the same treatment across several specialties, a global research review found.

The review found differences in care for conditions including cardiovascular disease, kidney disease and Parkinson’s, with women less likely to receive some active treatments.

Of 38 studies analysed, 33 found women were less likely than men to be offered active treatment.

Researchers at the University of St Andrews found women with myocardial infarction, heart failure or an irregular heartbeat were more likely to receive medication, while men were more likely to undergo coronary bypass surgery, stenting or other surgical treatment.

Women were also less likely to be prescribed statins.

Men with Parkinson’s were more likely to be referred for deep brain stimulation.

Men with liver failure were more likely to receive a transplant, while women with kidney disease requiring dialysis were less likely to receive permanent access and spent longer using a catheter.

Women were also less likely to receive opioids for pain management.

The researchers found no significant difference between women and men in treatment for stroke or diabetes, while women were more likely to receive treatment for dementia.

None of the studies identified clinical guidelines recommending different treatment based on sex.

Researchers said this suggested the differences could not be explained by the need for different clinical approaches to women’s health.

Dr Andrew O’Malley, who co-led the study, said: “For clinicians, the findings are a prompt to check whether treatment is being offered on clinical grounds rather than assumption.”

He said studies showed doctors more often attributed women’s symptoms to anxiety and made more diagnostic errors with female patients, even when test results were positive.

Dr Miriam Veenhuizen, honorary lecturer in the School of Medicine at St Andrews, said: “While the direction of the findings was not a surprise, the consistency was. The same pattern appeared in cardiology, surgery, transplant medicine and emergency care, and it survived statistical adjustment in most studies.”

Continue Reading

Menopause

Menopause frequently missing from electronic health records – study

Published

on

Menopause is often absent from women’s electronic health records, a study of nearly 396,000 women has found.

Researchers found menopause appeared almost seven times more often in participant surveys than in electronic health records (EHRs).

The findings suggest important reproductive health information, including age at menopause, may often be missing from health records used for research.

Audrey Hendricks, associate professor of bioinformatics at CU Anschutz and the study’s principal investigator, said: “Ultimately, we cannot study what we do not measure. We cannot treat what we do not know.

“Menopause has enormous implications for women’s health, but if we don’t consistently capture when menopause occurs and other important reproductive health information, we limit our ability to understand how this transition affects disease risk and health outcomes.”

Researchers at the University of Colorado Anschutz analysed data from women taking part in the National Institutes of Health’s All of Us Research Program.

They compared menopause information reported by participants in surveys with menopause diagnoses recorded in their electronic health records.

Around 193,000 menopause observations were identified in survey data, compared with approximately 28,000 diagnoses in EHR data.

Menopause was documented in electronic health records for only about 7 per cent of women in the dataset.

Nearly all participants with a menopause diagnosis recorded in their EHR also reported menopause in survey data. However, substantially fewer women had menopause documented in their health records.

Other important information was also frequently unavailable, including age at menopause, which researchers may use when examining links between menopause and chronic disease risk.

Menopause is a physiological transition that can affect cardiometabolic health and many other aspects of women’s health.

Researchers said relatively little is known about how factors including the timing and type of menopause influence health outcomes across diverse populations.

Large-scale programmes such as All of Us combine participant surveys, electronic health records and genomic data, but menopause-related research depends on relevant reproductive health information being available.

Missing menopause information can make it harder to investigate how the transition relates to health and disease.

The findings may also help researchers using All of Us data define menopause-related study populations, design studies and estimate how many participants are needed.

Hendricks said: “We have an enormous opportunity to use large-scale datasets to understand women’s health across the menopause transition and to identify who may be at greater risk for disease.

“But we need to make sure that the information researchers need is actually being collected.

“We must do a better job of capturing women’s health information, including reproductive health and measures related to menopause.”

Researchers said more complete and consistent collection of menopause and reproductive health information could help future studies examine factors such as age at menopause and their relationship with disease risk and health outcomes.

Continue Reading

Diagnosis

FDA approves AstraZeneca breast cancer drug

Published

on

The FDA has granted accelerated approval to AstraZeneca drug Etcamah for certain adults with advanced breast cancer carrying an ESR1 mutation.

Etcamah, also known as camizestrant, was approved in combination with a CDK4/6 inhibitor, either abemaciclib, palbociclib or ribociclib.

The treatment is for adults with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer when an estrogen receptor-1 (ESR1) mutation is detected during aromatase inhibitor and CDK4/6 inhibitor therapy using an FDA-authorised test.

ESR1 mutations are acquired resistance mutations that tumours may develop during treatment with aromatase inhibitors, a type of endocrine therapy commonly used as a front-line treatment for locally advanced or metastatic breast cancer.

Fewer than 5 per cent of patients have the mutation when HR-positive metastatic breast cancer is diagnosed, according to the FDA. After disease progression on an aromatase inhibitor, nearly 40 per cent have the mutation.

Acting FDA commissioner Kyle Diamantas said: “Women living with metastatic breast cancer face an uphill battle as their tumors continuously evolve to escape treatment.

“We owe them every weapon in our arsenal.

“Today’s approval delivers a win to these patients by granting them a targeted therapy designed specifically to overcome resistance, giving them more time before their disease progresses.”

The accelerated approval programme allows earlier approval of drugs that treat serious conditions and fill an unmet medical need based on surrogate or intermediate endpoints.

For Etcamah, approval was based on how long patients lived without their disease worsening, measured from when the resistance mutation was first detected in their blood.

The FDA said it has not yet been confirmed whether intervening when the mutation is detected, rather than waiting until disease progression is confirmed, results in a clinically meaningful benefit. Confirmatory studies are therefore required to verify and describe clinical benefit.

Angelo de Claro, director of the FDA’s Oncology Center of Excellence, said: “I commend both the FDA and the sponsor for their commitment to advancing cancer care and securing this accelerated approval.

“This marks the first FDA approval of a cancer therapy guided by the detection of a resistance mutation in circulating tumor DNA (ctDNA) before imaging tests show that the disease is progressing.

“But additional evidence is needed to confirm clinical benefit.”

Circulating tumour DNA, or ctDNA, consists of small pieces of tumour DNA released into the blood and can allow earlier molecular detection of resistance mutations.

The FDA also authorised the Guardant360 CDx assay as a companion diagnostic to identify patients with breast cancer who have ESR1 mutations for treatment with camizestrant.

Efficacy was assessed in a clinical trial comparing a switch to Etcamah plus a CDK4/6 inhibitor with continued treatment using an aromatase inhibitor plus a CDK4/6 inhibitor.

Estimated median progression-free survival was 16 months in the Etcamah group, compared with 9.2 months in the aromatase inhibitor group.

Etcamah’s prescribing information includes a boxed warning about the risk of irregular heart rhythm when taken with certain other medicines. It also includes warnings about an abnormally slow heart rate and potential harm to an unborn baby.

The FDA convened its Oncologic Drugs Advisory Committee for the application on 30 April 2026.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.